Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for hormone-driven ovarian cancer Under the terms of the agreement, Northway Biotech ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for hormone-driven ovarian cancer WALTHAM, MASSACHUSETTS / ACCESS Newswire / May 21, ...

Represents significant milestone in the development of KAD101, a novel biologic prolactin receptor antagonist, being initially developed for the treatment of platinum resistant ovarian cancer (PROC) ...

VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission ...